Press Releases

Press Releases
Date Title and Summary View
Jul 5, 2017 Celgene accelerates its immuno-oncology strategy in solid tumors with acquisition of worldwide rights, rest of world outside Asia, to BeiGene's PD-1 inhibitor BGB-A317; Pivotal BGB-A317 solid tumor studies planned for 2018 Collaboration maximizes potential for best-in-class PD-1-based ...
Jul 5, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, July 27, 2017 at 9 a.m. ET to discuss second quarter 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Jun 22, 2017 Powerful, New Portraits Aim to Inspire People With Plaque Psoriasis or Psoriatic Arthritis to Show More of Their True Selves SUMMIT, N.J.--(BUSINESS WIRE)-- Award-winning portrait photographer Martin Schoeller along with 12-time Olympic medalist and New York Times best-selling author Dara To...
Jun 19, 2017 Presentations highlight innovative research in multiple disease areas including multiple myeloma, lymphoma, leukemia, myelodysplastic syndromes and beta-thalassemia BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that data from a broad range ...
Jun 17, 2017 Interim data from the study evaluating the investigational chemotherapy-free R2 combination regimen, presented at ASCO and expanded data presented at ICML Results showed clinical activity across indolent non-Hodgkin lymphomas, marginal zone and follicular histologies, as well as responses...
Jun 14, 2017 Data showed positive trend in multiple disease measures versus placebo Results presented at the Annual European Congress of Rheumatology (EULAR) 2017 BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporat...
Jun 6, 2017 40.3% Overall Response Rate (ORR) with Median Duration of Response of 5.8 Months and 19.3% Complete Response (CR) Rate with Median Duration of Response of 8.8 Months in Patients With a CR Overall Safety Profile was Consistent with Previously Reported Data Simultaneous Online Public...
Jun 5, 2017 - 100% of the 15 evaluable patients in active dose cohorts (doses above 50 x 106) achieved an objective response; overall response rate (ORR) across all cohorts (n=18) is 89% - - 73% of evaluable patients in active dose cohorts achieved a very good partial response (VGPR) or better; 27% complete r...
Jun 1, 2017 - Companies expect to report top-line results from the Phase 3 studies in mid-2018 - SUMMIT, N.J. & CAMBRIDGE, Ma.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that they have completed target enrollment in the MEDALIS...
May 22, 2017 Study met the primary endpoint of annualized relapse rate (ARR) and key secondary MRI endpoints of T2 and GdE lesions, compared to interferon (IFN) β-1a (Avonex®); a very low rate of disability progression observed across the three treatment groups in the pooled analysis; disability endpoint not met ...
1
... NextLast
Add to Briefcase = add release to Briefcase